Trusted Resources: News & Meetings
Latest announcements and gatherings
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration With JCR Pharmaceuticals
Takeda Pharmaceutical Company Limited and JCR Pharmaceuticals Co., Ltd. announced a geographically-focused exclusive collaboration and license agreement to commercialize JR-141 (INN: pabinafusp alfa), an investigational, next-generation recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase (IDS) enzyme for the treatment of Hunter syndrome (also known as Mucopolysaccharidosis type II or MPS II).
Hunter syndrome is caused by a deficiency of IDS and manifests in different forms. JR-141, applied with J-Brain Cargo®, JCR’s proprietary blood-brain barrier (BBB) technology, is engineered to transport the therapeutic enzyme across the BBB to directly reach the brain and address both the somatic and neuronopathic manifestations of the disease, which can lead to progressive cognitive decline.
BookmarkRelated Content
-
Impaired Neural Differentiation of MPS IIIA Patient Induced Pluripotent Stem Cell-Derived Neural Progenitor CellsMucopolysaccharidosis type IIIA (MPS III...
-
How One Mother Turned Her Son’s Rare Disease Diagnosis Into an Opportunity to Help OthersMoira Taffarello and her husband have ex...
-
Emily Wants to Show Other Caregivers the Importance of Taking Care of YourselfPeople often make admiring comments to c...
-
University of Minnesota – Mucopolysaccharidosis (MPS) CenterOur MPS Center is internationally recogn...
-
Loss of Function of Mutant IDS Due to Endoplasmic Reticulum-Associated Degradation: New Therapeutic Opportunities fo...Mucopolysaccharidosis type II (MPS II) r...
-
Aiden and Aj’s Story – Living With Hunter Syndromehttps://www.youtube.com/watch?v=9rt-e3Ky...
-
Mucopolysaccharidoses Diagnosis in the Era of Enzyme Replacement Therapy in EgyptUndegraded glycosaminoglycans (GAGs) ind...
Powered by
